Rabinowicz, Noa , Mangala, Lingegowda S. , Brown, Kevin R. , CHECA RODRIGUEZ, CINTIA, Castiel, Asher , Moskovich, Oren , Zarfati, Giulia , Trakhtenbrot, Luba , Levy-Barda, Adva , Jiang, Dahai , Rodriguez-Aguayo, Cristian , Pradeep, Sunila , van Praag, Yael , Lopez-Berestein, Gabriel , David, Ahuvit , Novikov, Ilya , Huertas, Pablo , Rottapel, Robert , Sood, Anil K. , Izraeli, Shai
No
Oncotarget
Article
Científica
1.942
18/04/2017
000399819700126
Advanced ovarian cancer is an incurable disease. Thus, novel therapies are required. We wished to identify new therapeutic targets for ovarian cancer. ShRNA screen performed in 42 ovarian cancer cell lines identified the centriolar replication factor STIL as an essential gene for ovarian cancer cells. This was verified in-vivo in orthotopic human ovarian cancer mouse models. STIL depletion by administration of siRNA in neutral liposomes resulted in robust anti-tumor effect that was further enhanced in combination with cisplatin. Consistent with this finding, STIL depletion enhanced the extent of DNA double strand breaks caused by DNA damaging agents. This was associated with centrosomal depletion, ongoing genomic instability and enhanced formation of micronuclei. Interestingly, the ongoing DNA damage was not associated with reduced DNA repair. Indeed, we observed that depletion of STIL enhanced canonical homologous recombination repair and increased BRCA1 and RAD51 foci in response to DNA double strand breaks. Thus, inhibition of STIL significantly enhances the efficacy of DNA damaging chemotherapeutic drugs in treatment of ovarian cancer.
STIL; centrosomes; ovarian cancer; DNA damage; genomic instability